Immune cytopenia after allogeneic haematopoietic stem-cell transplantation : challenges, approaches, and future directions
Copyright © 2021 Elsevier Ltd. All rights reserved..
Immune-mediated cytopenia after allogeneic haematopoietic stem-cell transplantation is rare. The pathophysiology of immune-mediated anaemia, thrombocytopenia, and neutropenia, which occur alone or in combination with other cytopenias, is unclear and most probably a consequence of immune dysregulation. Risk factors for this complication have been identified in retrospective studies but these should be interpreted with caution and should not be generalised to this heterogeneous patient population. Diagnosis is challenging, requires awareness of such complications, and has to be differentiated from a multitude of other, and sometimes overlapping, possible complications. The clinical course of immune-mediated cytopenia is highly variable. Treatment requires an interdisciplinary approach and ranges from observation to symptomatic measures and directed therapies. Intensive immunosuppression is associated with an increased risk of infections and relapse, and current treatments are based on approaches in patients who have not undergone transplantation. Plasma cell-directed therapies, immunomodulation, and receptor-stimulating agents can be used to treat immune-mediated cytopenia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
The Lancet. Haematology - 8(2021), 3 vom: 04. März, Seite e229-e239 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baur, Katharina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents, Immunological |
|---|
| Anmerkungen: |
Date Completed 09.03.2021 Date Revised 09.03.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2352-3026(20)30404-X |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321942744 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321942744 | ||
| 003 | DE-627 | ||
| 005 | 20231225180956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2352-3026(20)30404-X |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM321942744 | ||
| 035 | |a (NLM)33636143 | ||
| 035 | |a (PII)S2352-3026(20)30404-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baur, Katharina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune cytopenia after allogeneic haematopoietic stem-cell transplantation |b challenges, approaches, and future directions |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2021 | ||
| 500 | |a Date Revised 09.03.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Immune-mediated cytopenia after allogeneic haematopoietic stem-cell transplantation is rare. The pathophysiology of immune-mediated anaemia, thrombocytopenia, and neutropenia, which occur alone or in combination with other cytopenias, is unclear and most probably a consequence of immune dysregulation. Risk factors for this complication have been identified in retrospective studies but these should be interpreted with caution and should not be generalised to this heterogeneous patient population. Diagnosis is challenging, requires awareness of such complications, and has to be differentiated from a multitude of other, and sometimes overlapping, possible complications. The clinical course of immune-mediated cytopenia is highly variable. Treatment requires an interdisciplinary approach and ranges from observation to symptomatic measures and directed therapies. Intensive immunosuppression is associated with an increased risk of infections and relapse, and current treatments are based on approaches in patients who have not undergone transplantation. Plasma cell-directed therapies, immunomodulation, and receptor-stimulating agents can be used to treat immune-mediated cytopenia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 700 | 1 | |a Buser, Andreas S |e verfasserin |4 aut | |
| 700 | 1 | |a Infanti, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Halter, Jörg P |e verfasserin |4 aut | |
| 700 | 1 | |a Passweg, Jakob R |e verfasserin |4 aut | |
| 700 | 1 | |a Holbro, Andreas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Haematology |d 2014 |g 8(2021), 3 vom: 04. März, Seite e229-e239 |w (DE-627)NLM244793018 |x 2352-3026 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2021 |g number:3 |g day:04 |g month:03 |g pages:e229-e239 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2352-3026(20)30404-X |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2021 |e 3 |b 04 |c 03 |h e229-e239 | ||